According to the 2003 IJDVL study, what was the mean percentage
improvement in acne severity with Azithromycin pulse therapy?

In the same study, what percentage of patients on Azithromycin
achieved >80% lesion clearance?

What was the Azithromycin dosing regimen used in the 2003 IJDVL
acne study?

Which adverse event was reported with Doxycycline but not with
Azithromycin in the IJDVL study?

What topical therapy was administered alongside both oral regimens in
the 2003 acne study?

What was the mean post-treatment acne severity index for patients on
Doxycycline, as reported in the study?

How was the study titled “Comparison of Oral Azithromycin Pulse
with Daily Doxycycline in Acne Vulgaris” designed?

What was the main clinical advantage of pulse Azithromycin therapy
shown in the IJDVL acne study?

What pharmacokinetic property of Azithromycin supports its pulse
dosing strategy?

According to the study, why is Azithromycin an appealing option for
adolescent acne patients?